An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies

Trial Profile

An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Tirabrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 04 Apr 2017 Results of long-term follow-up (3-year, n=28) of ONO/GS-4059 in chronic-lymphocytic-leukaemia patients, published in the Blood Journal.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top